This season belongs to the franchise you already have, not the one you just launched
Across five reporters, the biggest product lines carried the quarter. Raised guidance came from established franchises, so the case for protecting and extending them is stronger than the launch narrative suggests.
The incumbents did the heavy lifting
Earnings season invites a story about new launches. The numbers tell a plainer one. In most of this material, the largest line was the one already on the market, and it was usually the one that moved guidance.
Sarepta reported $323.8 million of net product revenue. PMO products contributed $240.3 million and ELEVIDYS $83.5 million, so the PMO line outsold the gene therapy by almost three to one. Sarepta raised the lower end of its revenue guidance by $50.0 million, and it attributed that to strong PMO performance.
Corcept's revenue rose 64 percent to $340.5 million. Korlym and its authorized generic brought in $249.1 million, nearly three-quarters of the total, while Lifyorli added $91.4 million. At Acadia, NUPLAZID's $202 million of net sales exceeded DAYBUE's $140 million. Ironwood's LINZESS had already sold $880 million in the U.S. year to date, more than its full-year 2025 total, and guidance for the line now implies growth above 35%.
The pattern is not that new products failed. It is that the base franchise remains the main source of earnings and of upgrades.
The best growth came from extending what exists
The most instructive example is Acadia's DAYBUE. Net sales rose 39% year over year, which Acadia attributed to strong uptake of DAYBUE STIX. Acadia raised its full-year DAYBUE guidance to $505–$520 million. This was not a new molecule. It was a product that is already marketed, made easier to use.
Corcept shows the same logic from the clinical side. It reported BELLA Part A results for Lifyorli in platinum-resistant ovarian cancer, with its most pronounced results in patients earliest in their course of treatment. Sarepta is building a growing evidence base for ELEVIDYS across the ambulatory population and for liver-safety risk mitigation. In each case the company is spending to deepen the franchise it owns, not just to find the next one.
Our position: the highest-return work in the sector this season was lifecycle management, meaning formulation, evidence and label breadth. It is less glamorous than a pipeline readout, and it is where the guidance raises came from.
The strongest counter-argument
The obvious objection is that new launches are what justify the valuation of these companies, and some of this season's best results came from them. PTC's Sephience generated $182 million of its $276 million in product revenue, and PTC lifted full-year product guidance to $960–$990 million. Moderna grew revenue 29%, raised its 2026 growth outlook to 15%–25% from up to 10%, and added mFLUSIVA as its fifth approved product. Corcept's Lifyorli has already contributed $91.4 million. A reader could fairly say that without launches there would be no future incumbents.
That is true, and we do not argue otherwise. But a launch becomes valuable only if it becomes a durable franchise, and this season's evidence is about what durable looks like. It looks like Ironwood's LINZESS, Corcept's Korlym and Acadia's NUPLAZID. Those lines are still being managed, extended and in some cases re-guided upward. Strong launch quarters are the start of that work, not a substitute for it.
What it means
Companies that treat the core franchise as a finished asset risk underinvesting in the product that supports most of their revenue. Companies that treat it as an asset to defend and extend can raise guidance without needing a new approval.
The distinction matters for how leaders allocate attention. A launch gets a command center. An established franchise often gets a maintenance budget. This season suggests that ordering is backwards.
— The Editor, CompePharma
What leaders should do
- Audit revenue concentration by product line, then fund lifecycle work (formulation, evidence, label breadth) for the franchise that carries the most revenue as seriously as a launch.
- Judge a new launch by whether it can become a durable franchise, and plan its second- and third-year evidence and convenience upgrades before the first-year numbers arrive.
- When raising guidance, say whether the increase comes from the established franchise or the new product, so investors and partners can see which engine is carrying the quarter.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
The second act is where this quarter's money was made
The strongest results this season came from extending assets already in market, through new labels, formulations and royalties, rather than from unproven launches. That strategy has a ceiling.
A fee schedule rate is not a durable price: coverage is the real asset
Medicare's full-rate payment for EsoGuard is a milestone, but case-by-case coverage and a pending reconsideration show why payer access, not list price, decides the economics.
Plan the exit before the readout: strategic alternatives shouldn't start after a miss
Longeveron, Theriva and Silence show how much optionality depends on when boards start thinking about the endgame. The best time is before the data arrive.